Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Intrinsic macrolide resistance of the Mycobacterium tuberculosis complex is inducible.

Literature DB >> 16801446

Intrinsic macrolide resistance of the Mycobacterium tuberculosis complex is inducible.

Abstract

Mycobacterium tuberculosis is intrinsically resistant to macrolides, a characteristic associated with expression of the erm(37) gene. This intrinsic resistance was found to be inducible with clarithromycin and the ketolide HMR3004. Furthermore, underlying the phenotypic induction was an increase in erm(37) mRNA levels.

Entities: Chemical Species

Mesh：

Substances：

Year: 2006 PMID： 16801446 PMCID： PMC1489773 DOI： 10.1128/AAC.00264-06

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

13 in total

1. In vitro activities of the ketolides telithromycin (HMR 3647) and HMR 3004 compared to those of clarithromycin against slowly growing mycobacteria at pHs 6.8 and 7.4.

Authors: N Rastogi; K S Goh; M Berchel; A Bryskier
Journal: Antimicrob Agents Chemother Date: 2000-10 Impact factor: 5.191

2. In-vitro activity of fluorinated quinolones and macrolides against drug-resistant Mycobacterium tuberculosis.

Authors: S E Hoffner; L Gezelius; B Olsson-Liljequist
Journal: J Antimicrob Chemother Date: 1997-12 Impact factor: 5.790

3. Molecular basis of intrinsic macrolide resistance in clinical isolates of Mycobacterium fortuitum.

Authors: Kevin A Nash; Yansheng Zhang; Barbara A Brown-Elliott; Richard J Wallace
Journal: J Antimicrob Chemother Date: 2004-12-08 Impact factor: 5.790

4. In vitro and in vivo activities of macrolide derivatives against Mycobacterium tuberculosis.

Authors: Kanakeshwari Falzari; Zhaohai Zhu; Dahua Pan; Huiwen Liu; Poonpilas Hongmanee; Scott G Franzblau
Journal: Antimicrob Agents Chemother Date: 2005-04 Impact factor: 5.191

5. Methyltransferase Erm(37) slips on rRNA to confer atypical resistance in Mycobacterium tuberculosis.

Authors: Christian Toft Madsen; Lene Jakobsen; Karolina Buriánková; Florence Doucet-Populaire; Jean-Luc Pernodet; Stephen Douthwaite
Journal: J Biol Chem Date: 2005-09-20 Impact factor: 5.157

6. Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium.

Authors: L Collins; S G Franzblau
Journal: Antimicrob Agents Chemother Date: 1997-05 Impact factor: 5.191

7. A new ketolide, HMR 3004, active against streptococci inducibly resistant to erythromycin.

Authors: A Rosato; H Vicarini; A Bonnefoy; J F Chantot; R Leclercq
Journal: Antimicrob Agents Chemother Date: 1998-06 Impact factor: 5.191

8. Clarithromycin is inactive against Mycobacterium tuberculosis.

Authors: C Truffot-Pernot; N Lounis; J H Grosset; B Ji
Journal: Antimicrob Agents Chemother Date: 1995-12 Impact factor: 5.191

9. Antituberculosis activity of clarithromycin.

Authors: J Luna-Herrera; V M Reddy; D Daneluzzi; P R Gangadharam
Journal: Antimicrob Agents Chemother Date: 1995-12 Impact factor: 5.191

10. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes.

Authors: Jo Vandesompele; Katleen De Preter; Filip Pattyn; Bruce Poppe; Nadine Van Roy; Anne De Paepe; Frank Speleman
Journal: Genome Biol Date: 2002-06-18 Impact factor: 13.583

16 in total

Review 1. Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria.

Authors: Barbara A Brown-Elliott; Kevin A Nash; Richard J Wallace
Journal: Clin Microbiol Rev Date: 2012-07 Impact factor: 26.132

Review 2. Antibiotic resistance mechanisms in M. tuberculosis: an update.

Authors: Liem Nguyen
Journal: Arch Toxicol Date: 2016-05-09 Impact factor: 5.153

Review 3. Importance of the genetic diversity within the Mycobacterium tuberculosis complex for the development of novel antibiotics and diagnostic tests of drug resistance.

Authors: Claudio U Köser; Silke Feuerriegel; David K Summers; John A C Archer; Stefan Niemann
Journal: Antimicrob Agents Chemother Date: 2012-09-24 Impact factor: 5.191

Review 4. World Health Organization group 5 drugs for the treatment of drug-resistant tuberculosis: unclear efficacy or untapped potential?

Authors: Kelly E Dooley; Ekwaro A Obuku; Nadza Durakovic; Vera Belitsky; Carole Mitnick; Eric L Nuermberger
Journal: J Infect Dis Date: 2012-07-17 Impact factor: 5.226

5. Rapid assessment of antibacterial activity against Mycobacterium ulcerans by using recombinant luminescent strains.

Authors: Tianyu Zhang; William R Bishai; Jacques H Grosset; Eric L Nuermberger
Journal: Antimicrob Agents Chemother Date: 2010-04-26 Impact factor: 5.191

6. Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline.

Authors: Payam Nahid; Sundari R Mase; Giovanni Battista Migliori; Giovanni Sotgiu; Graham H Bothamley; Jan L Brozek; Adithya Cattamanchi; J Peter Cegielski; Lisa Chen; Charles L Daley; Tracy L Dalton; Raquel Duarte; Federica Fregonese; C Robert Horsburgh; Faiz Ahmad Khan; Fayez Kheir; Zhiyi Lan; Alfred Lardizabal; Michael Lauzardo; Joan M Mangan; Suzanne M Marks; Lindsay McKenna; Dick Menzies; Carole D Mitnick; Diana M Nilsen; Farah Parvez; Charles A Peloquin; Ann Raftery; H Simon Schaaf; Neha S Shah; Jeffrey R Starke; John W Wilson; Jonathan M Wortham; Terence Chorba; Barbara Seaworth
Journal: Am J Respir Crit Care Med Date: 2019-11-15 Impact factor: 21.405

7. A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae.

Authors: Kevin A Nash; Barbara A Brown-Elliott; Richard J Wallace
Journal: Antimicrob Agents Chemother Date: 2009-01-26 Impact factor: 5.191